L'entreprise OGD2 PHARMA est spécialisée en recherches, études et analyses spécialisées.
27 May 2016 : In our efforts to fight brain cancer we are proud to annonce the publication of new data supporting the therapeutic activity of our antibody in brain tumors. Research was performed in collaboration with Centre de Recherche Contre le Cancer de Nantes Angers (CRCNA) and supported by Agence Nationale de la Recherche (ANR). Fleurence 2016 Oncotarget – Targeting GBM Abstract: There are still unmet medical needs in the treatment of glioblastoma, the most common and the most aggressive glioma of all brain tumors. Here, we found that O-acetyl GD2 is expressed in surgically resected human glioblastoma tissue. In addition, we demonstrated that 8B6 monoclonal antibody specific for O-acetylated GD2 could effectively inhibit glioblastoma cell proliferation in vitro and in vivo. Taken together, these results indicate that O-acetylated GD2 represents a novel antigen for immunotherapeutic-based treatment of high-grade gliomas.
